Jan. 11, 2007 — The Society for Cardiovascular Angiography and Interventions (SCAI) today released a clinical alert ...
Stents Drug Eluting
This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.
Jan. 5, 2007 — A French court has ruled that Abbott Laboratories’ Xience V drug-eluting coronary stents infringe patents ...
Diagnostic & Invasive Cardiology editor Kim Phelan spoke with Jeff Mirviss, vice president of Stent Marketing at Boston ...
The FDA panel that convened for an intense, two-day review of drug-eluting stents last week heard key testimony from ...
The FDA panel that is re-evaluating the safety of drug-eluting stents convenes Dec. 7 and 8 at the Hilton Washington DC ...
The FDA will revisit a device tomorrow that it cleared for U.S. sale three years ago — drug-eluting stents will be the ...
Recent downplay of the media’s attention to DES-related thrombosis during both the TCT and AHA conferences this fall may ...
Two novel polymer-free drug-eluting stent coating technologies tested in a comparative animal study has concluded with ...
The stent market will have a distinctly different look after Johnson & Johnson completes its acquisition of Conor ...
The tiny tools of interventional cardiology known as drug-eluting stents (which happen to comprise a gargantuan U.S ...
The first third-generation drug-eluting stent is now available to physicians and patients in many markets around the ...
A Netherlands study comparing two-year outcomes of a series of 708 consecutive diabetic patients (25 percent insulin ...
ACC together with AHA and other key healthcare organizations, has launched "Door to Balloon (D2B): An Alliance ...
The Certification Commission for Healthcare Information Technology is inviting organizations to submit their ambulatory ...
Results from the Danish SORT-OUT II study, the largest randomized trial to date comparing Taxus and Cypher drug-eluting ...